What GLP-1 is
GLP-1 stands for glucagon-like peptide-1. It is a short peptide hormone released mainly by L-cells in the lining of the small intestine and colon after you eat. It belongs to a family of gut hormones called incretins, which link the arrival of food in the gut to the body's hormonal response.
Natural GLP-1 is broken down within a couple of minutes by an enzyme called dipeptidyl peptidase-4 (DPP-4). That extremely short half-life is the reason the hormone itself was never a practical medicine, and why drug development focused on longer-lasting molecules that activate the same receptor.
How it works in the body
GLP-1 binds to the GLP-1 receptor, which is found in the pancreas, the gut, the heart and blood vessels, the kidneys and several regions of the brain. Activating that receptor produces a cluster of effects that mostly point in the same direction: less glucose in the blood, and less appetite.
- Insulin release, glucose-dependent. GLP-1 amplifies insulin secretion only when blood glucose is elevated, which is why receptor activation alone carries a low risk of hypoglycemia compared with insulin itself.
- Glucagon suppression. It reduces glucagon output from the pancreas, lowering the amount of glucose released by the liver after meals.
- Gastric emptying. It slows the rate at which the stomach empties, which flattens the post-meal glucose rise and prolongs fullness.
- Central appetite signalling. Receptors in the hypothalamus and brainstem influence satiety and food reward — the part most people notice as reduced appetite and quieter food thoughts.
GLP-1 receptor agonists
The medicines people mean when they say "a GLP-1" are GLP-1 receptor agonists: engineered peptides that resist DPP-4 breakdown and stay active for hours or days instead of minutes. Exenatide was the first, followed by liraglutide, dulaglutide and semaglutide.
Newer molecules go further by hitting more than one receptor. Tirzepatide activates both the GLP-1 and GIP receptors. Retatrutide, still in clinical development, is designed as a triple agonist at the GLP-1, GIP and glucagon receptors — the reason it is sometimes loosely called "GLP-3," a label that is marketing shorthand, not a real hormone.
Our retatrutide guide goes through that triple-agonist research in detail.
What the trials show
Unlike most topics in the peptide conversation, GLP-1 receptor agonists have been studied in large, randomized, placebo-controlled trials with thousands of participants and years of follow-up. The broad findings are consistent.
- Glucose control. In type 2 diabetes, these agents reliably lower HbA1c relative to placebo, with the newer and dual-agonist molecules generally producing larger reductions than the older ones.
- Body weight. Weight loss in trials scales with the molecule and the dose studied, ranging from modest with the earliest agents to substantial with semaglutide and tirzepatide at the highest studied doses.
- Cardiovascular outcomes. Several agents have cardiovascular outcome trials showing reduced rates of major adverse cardiovascular events in high-risk populations — an unusual result for a weight or glucose drug.
- Regain after stopping. Withdrawal studies consistently show that much of the lost weight returns after treatment stops, which is why the research frames these as chronic therapies rather than courses.
Get the weekly research dispatch
One email. New peer-reviewed research, distilled. No spam, unsubscribe in one click.
Beyond weight and glucose
Because GLP-1 receptors are widespread, researchers are studying effects well outside metabolism. Active areas include kidney outcomes in chronic kidney disease, fatty liver disease, sleep apnea, osteoarthritis-related pain, and early work on addiction and neurodegenerative conditions.
Some of these have completed trials with positive results; many are early or observational. A plausible mechanism and an interesting signal are not the same thing as a demonstrated benefit, and this is exactly the area where headlines tend to run ahead of data.
Side effects and open questions
- Gastrointestinal effects. Nausea, vomiting, diarrhea and constipation are the most common reported effects in trials, usually strongest when a dose is increased and often easing over time.
- Muscle and lean mass. A meaningful share of weight lost is lean mass, as with most substantial weight loss. How much that matters long term, and how much resistance training and protein intake offset it, is an active research question.
- Less common risks. Trials and labels describe risks including pancreatitis, gallbladder disease and, based on rodent data, thyroid C-cell tumors — which is why some of these products carry specific contraindications.
- Long-term use. These are relatively new as long-term therapies in people without diabetes. Decades-long safety data does not exist yet.
Regulatory status
Several GLP-1 receptor agonists are FDA-approved prescription medicines with specific indications. That approval applies to the specific approved product, made under pharmaceutical manufacturing standards and used under medical supervision.
It does not extend to compounded, "research-grade," or grey-market versions of these peptides. The FDA has issued warnings about compounded and counterfeit semaglutide and tirzepatide products, including dosing errors and unverified ingredients. We do not cover sourcing, dosing or protocols on this site, and nothing here should be read as suggesting any non-prescription use.
Common questions
Is Ozempic a GLP-1?
Ozempic is a brand name for semaglutide, which is a GLP-1 receptor agonist. The hormone GLP-1 and the medicines that activate its receptor are related but not the same thing.
What does GLP-1 stand for?
Glucagon-like peptide-1, named for its structural similarity to the hormone glucagon.
Can you raise GLP-1 naturally?
Eating raises GLP-1 by definition, and research has examined how meal composition, fiber, protein and gut microbiota influence the size and duration of that release. The effects studied are far smaller and shorter-lived than what pharmacological receptor agonists produce, and "natural GLP-1 booster" supplement claims are generally not supported by controlled trials.
Are GLP-1 peptides sold online the same as prescription versions?
No. Products sold outside the regulated prescription channel are not held to the same identity, purity or manufacturing standards, and regulators have documented contaminated and mislabeled examples. This guide is educational and does not address obtaining or using them.
Where to go from here
We track new metabolic, longevity and performance research as it publishes and write it up with full citations so you can read the underlying studies yourself.